Vedolizumab for induction and maintenance of remission in ulcerative colitis

Clicks: 367
ID: 115472
2014
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Moderate to high quality data from four studies shows that vedolizumab is superior to placebo for induction of clinical remission and response and endoscopic remission in patients with moderate to severely active ulcerative colitis and prevention of relapse in patients with quiescent ulcerative coli …
Reference Key
sj2014thevedolizumab Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bickston SJ;Behm BW;Tsoulis DJ;Cheng J;MacDonald JK;Khanna R;Feagan BG;;
Journal The Cochrane database of systematic reviews
Year 2014
DOI
DOI not found
URL
https://www.pubmed.gov/25105240/
Keywords
systematic review meta-analysis National Center for Biotechnology Information NCBI NLM MEDLINE review humans pubmed abstract nih national institutes of health national library of medicine randomized controlled trials as topic Antibodies Monoclonal Brian G Feagan Humanized / therapeutic use* Colitis secondary prevention pmid:25105240 doi:10.1002/14651858.cd007571.pub2 stephen j bickston brian w behm humanized / adverse effects ulcerative / prevention & control ulcerative / therapy* induction chemotherapy / methods* maintenance chemotherapy / methods*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.